Table 3 Independent prognostic value of the accumulation of driver alterations for TTFT

From: Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia

Variable

HR (95% CI)

P-value

Binet stage (B/C vs A)

2.44 (1.60–3.74)

<0.001

No. drivers (0, 1, 2, 3, ⩾4)

1.44 (1.21–1.72)

<0.001

SF3B1 (mut vs unmut)

2.02 (1.39–2.94)

<0.001

IGHV (unmut vs mut)

2.07 (1.35–3.19)

0.001

ATM (mut/deletion vs wt)

1.82 (1.19–2.27)

0.006

Age at sampling (>65 vs ⩽65 years)

0.66 (0.48–0.91)

0.011

  1. N=307, events=146, competing events=27. Starting model: IGHV, Binet stage, age at sampling, gender, TP53 aberration (mutation/deletion), ATM aberration (mutation/deletion), SF3B1 mutation and number of driver alterations (not including TP53, ATM and SF3B1 mutations, neither del(17p) nor del(11q)).
Back to article page